In the management of diarrhea-predominant IBS (IBS-D)…

The New Art of Barrier Restoration

Adding EnteraGam™ helps restore the barrier function of the intestinal mucosa

  • Goes beyond symptom management by targeting multiple factors in IBS-D

  • Significantly reduced the number of days with GI-related symptoms in a clinical trial of patients with IBS-D9

  • Has been safely used in clinical studies up to 1 year in length and has no restrictions on length of therapy

  • Is easily dissolved in liquids or mixed with soft foods
    (avoid acidic liquids and foods)
Important Safety Information: EnteraGam™ contains beef protein; therefore, patients who have an allergy to beef or any component of EnteraGam™ should not take this product.
Please see full Important Safety Information in Safety section and full Prescribing Information including contraindications in PI section.
References: 1. Asmuth DM, Albanese A, Garcia J-C, et al. Serum-derived bovine immunoglobulin (SBI) reduces stool frequency/gastrointestinal (GI) symptoms and reduces systemic immune activation in subjects with HIV enteropathy. Abstract presented at: 19th Conference on Retroviruses and Opportunistic Infections; March 5-8, 2012; Seattle, WA. 2. Asmuth DM, Ma Z-M, Albanese A, et al. Oral serum-derived bovine immunoglobulin improves duodenal immune reconstitution and absorption function in patients with HIV enteropathy. AIDS. doi:10.1097/QAD.0b013e328362e54c. 3. Lembcke JL, Peerson JM, Brown KH. Acceptability, safety, and digestibility of spray-dried bovine serum added to diets of recovering malnourished children. J Pediatr Gastroenterol Nutr. 1997;25(4):381-384. 4. Orphan Drug Act. FDA website. http://www.fda.gov/regulatoryinformation/ legislation/federalfooddrugandcosmeticactfdcact/significantamendmentstothefdcact/orphandrugact/default.htm. Accessed May 8, 2013. 5. Camilleri M. Peripheral mechanisms in irritable bowel syndrome. N Engl J Med. 2012;367(17):1626-1635. 6. Philpott H, Gibson P, Thien F. Irritable bowel syndrome—an inflammatory disease involving mast cells. Asia Pac Allergy. 2011;1(1):36-42. 7. Barbara G, Cremon C, Carini G, et al. The immune system in irritable bowel syndrome. J Neurogastroenterol Motil. 2011;17(4):349-359. 8. Guilarte M, Santos J, de Torres I, et al. Diarrhoea-predominant IBS patients show mast cell activation and hyperplasia in the jejunum. Gut. 2007;56(2):203-209. 9. Wilson D, Weaver E, Klein GL, Shaw AL, Evans M, Cohn J. Efficacy of serum-derived bovine immunoglobulin protein isolate (SBI) in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). Gastroenterology. 2013;144(5)(suppl 1):S-233. Abstract Sa1218. 10. Data on file. Entera Health, Inc.